Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Dose-ranging study of SGLT2 inhibitor JNJ-28431754 versus placebo with sitagliptin reference in type 2 diabetes
2007-006693-28Phase 2Completed
- Sponsor
- Janssen Pharmaceutical
- Start
- Feb 2008
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial of canagliflozin in type 2 diabetes mellitus (T2DM) (5 arms), sponsored by Janssen Pharmaceutical. Primary endpoints: Change in hemoglobin A1c from baseline to Week 12, Pharmacokinetics of JNJ-28431754 and 2 more. Started Feb 2008; status: completed.
02
Drugs
canagliflozin
03
Conditions
type 2 diabetes mellitus (T2DM)
Beyond the preview
Go deeper on 2007-006693-28.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2007-006693-28.